Amphista Therapeutics Achieves Breakthrough in Cancer Target Degradation
Amphista Therapeutics, a leader in next-generation targeted protein degradation (TPD), has published a study in Nature Communications demonstrating a novel mechanism for degrading the key cancer target BRD9 using its proprietary Targeted Glue small molecule degrader.
The company's Chief Scientific Officer, Louise Modis, PhD, commented:
The deep expertise of our scientists led to the successful integration of the favorable performance characteristics of earlier generation PROTACs and conventional molecular glues but with key limitations designed-out.
Author's summary: Amphista Therapeutics publishes breakthrough cancer research.
More News
- Budget jitters see construction forecasts plummet
- The environmental impact of the 2026 World Cup
- After Service Dog Helped her Journey to Recovery, Grad Student is Spreading the Word About Their Important Role
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- Pirates Listed as Potential Fit for Trent Grisham, Luis Arráez and Other Top Free Agents
- 2 US Navy aircraft crash in South China Sea
- ICYMI: AAO 2025 showcases new technologies and continued research | Ophthalmology Times - Clinical Insights for Eye Specialists
- Three resilient UK multinationals global managers are excited about | Trustnet
- Philippines economy to grow 5.6% in 2025 – Fitch
- OpenAI's Work With The Julliard School Has A Catch